51˶

Getting Prostate Cancer Drugs Sooner; Limiting Toxic Emissions; FTC Sues 'Charity'

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

Progression-free survival reasonably and could bring new therapies to patients about 2 years faster if used as the primary endpoint in clinical studies. (University College London, Journal of Clinical Oncology)

Adding to cancer care reduced patients' pain, depression, and fatigue and improved quality of life. (University of Pittsburgh Medical Center, The Lancet)

Worsening may increase the risk of developing cancer. (Cancer)

The Environmental Protection Agency announced a final rule to limit to reduce the risk of cancer among people living near commercial sterilization facilities.

CAR T-cell therapy targeting two different proteins showed early promise for slowing the growth of . (Penn Medicine, Nature Medicine)

Nurix Therapeutics announced that the FDA has lifted a partial clinical hold on a phase I trial of NX-2127, the company's .

Could data from internet searches be used to , possibly well before a patient sees a doctor for evaluation? (Imperial College London, BMC Public Health)

About a third of patients with responded to the investigational antibody-drug conjugate (ADC) disitamab vedotin, RemeGen announced.

Patients with heavily pretreated and no prior exposure to pegylated liposomal doxorubicin had significantly improved survival when treated with tumor-treating fields therapy and paclitaxel. (BioSpace)

Patients with relapsed/refractory lived significantly longer with the ADC brentuximab vedotin (Adcetris) plus lenalidomide (Revlimid) and rituximab (Rituxan) versus lenalidomide-rituximab alone, Pfizer announced.

The Federal Trade Commission and 10 states have sued the Cancer Foundation Fund International for deceptive practices that persuaded donors to contribute more than $18 million.

Decisions in two cases pending before the Supreme Court and one in an appeals court could have a in the U.S. (Association for Clinical Oncology)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined 51˶ in 2007.